



1542 *EB*

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
11245/46605

Application Number
09/996,954

Filing Date
November 30, 2001

Examiner
To be assigned

Art Unit
1642

Invention Title
**TREATMENT OF REFRACTORY HUMAN
TUMORS WITH EPIDERMAL GROWTH FACTOR
RECEPTOR ANTAGONISTS**

Inventor(s)
Harlan W. WAKSAL

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the
United States Postal Service with sufficient postage as first class mail in an envelope
addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-
1450 on

Date: October 1, 2003

By: *Kathryn M. Lumb*
Kathryn M. Lumb (Reg. No. 46,885)

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97(c) and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the references listed on the attached modified PTO Form No. 1449 to the attention of the Examiner. It is respectfully requested that the references be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. Except as otherwise indicated, copies of the references are not enclosed since they were previously cited by or submitted to the Patent Office in prior patent application Serial No. 09/840,146, filed April 24, 2001, which is relied upon for an earlier filing date under 35 U.S.C. 120.
3. The filing of this Information Disclosure Statement and the attached PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
4. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. § 1.17(p) (submission of an information disclosure statement under § 1.97(c)) fee of **\$180.00** to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. The Commissioner is also authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 11-0600.

Dated: October 1, 2003

By:

Kathryn M. Lumb
Kathryn M. Lumb
(Reg. No. 46,885)
Kenyon & Kenyon
One Broadway
New York, New York 10004
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)
CUSTOMER NO. 26646

10/09/2003 HROCHA1 00000025 110600 09996954

01 FC:1006 100.00 DA



**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT
BY APPLICANT PTO-1449**

ATTY. DOCKET NO.
11245/46605

SERIAL NO.
09/996,954

APPLICANT
WAKSAL et al.

FILING DATE
November 30, 2001

GROUP
1642

U. S. PATENT DOCUMENTS

* reference enclosed

EXAMINER'S INITIALS	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE
	* 5,616,582	April 1, 1997	Barker			
	* 5,558,864	September 24, 1996	Bendig et al.			
	5,891,996	April 6, 1999	Mateo de Acosta del Rio et al			
	6,217,866	April 17, 2001	Schlessinger et al.			
	U.S. Application Serial No. 09/809,924	Filed March 16, 2001	Rubin			

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION	
						YES	NO
	WO 00/31048	June 2, 2000		PCT			
	WO 98/33798	August 6, 1998		PCT			
	WO 97/42187	November 13, 1997		PCT			
	WO 97/30034	August 21, 1997		PCT			
	WO 97/27199	July 31, 1997		PCT			
	WO 96/33980	October 31, 1996		PCT			
	WO 96/30347	October 3, 1996		PCT			

OTHER DOCUMENTS

* reference enclosed

EXAMINER'S INITIALS	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	* Moyer et al., "Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, in an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase" Cancer Res., vol. 57, No. 21, November 1, 1997 pp. 4838-4848
	* Pollack et al., "Inhibition of Epidermal Growth Factor Receptor-Associated Tyrosine Phosphorylation in Human Carcinomas with CP-358, 774: Dynamics of Receptor Inhibition in Situ and Antitumor Effects in Athymic Mice", J. Pharmacol., vol. 291, No. 2, November 1999, pp 739-748
	* Rowinsky, et al., "Dose-Schedule-Finding, Pharmacokinetic (PK), Biologic, and Functional Imaging studies of OSI-774, a Selective Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase (TK) Inhibitor", Abstract 5 (Presented at the 37 th Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001
	* Anido et al., "Inhibition by ZD1839 (Iressa) of Epidermal Growth Factor (EGF) and Heregulin Induced Signaling Pathways in Human Breast Cancer Cells", Abstract 1712 (Presented at the 37 th Annual Meeting of ASCO), San Francisco, CA 12-15 May 2001



EXAMINER'S INITIALS		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		* Hidalgo et al., "Inhibition of the Epidermal Growth Factor Receptor (EGFR) by OSI-774, A specific EGFR Inhibitor in Malignant and Normal Tissues of Cancer Patients", Abstract 281 (Presented at the 37th Annual Meeting of ASCO), San Francisco, CA, 12-15 May 2001
		* Punt, "New Drugs in the Treatment of Colorectal Carcinoma", Cancer, Vol. 83, No. 4, August 15, 1998, pp.679-689
		Y. Han, et al. "Preferential Inhibition of Glioblastoma Cells with Wild-Type Epidermal Growth Factor Receptors by a Novel Tyrosine Kinase Inhibitor Ethyl-2,5-Dihydroxycinnamate", Oncology Research, vol. 9, 1997, pp. 581-587
		C.R. Divgi, et al." Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients with Squamous Cell Lung Carcinoma", Journal of Nat'l Cancer Institute, vol. 83, no. 2, January 16, 1991, pp. 97-104
		A. B. Miller et al., "Reporting Results of Cancer Treatment", Cancer, vol. 47, no. 1, January 1, 1981, pp. 207-214
		Stedman's Medical Dictionary, 25 th Edition, p. 1338
		Pfister, et al., Abstract, 1667, 35 th Annual Meeting of ASCO, 1999
		Siu, et al., Abstract, 1498, 35 th Annual Meeting of ASCO, 1999

* reference enclosed

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	